Core One Labs Stock (OTC:CLABF), Trade Ideas

Core One Labs

Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.

Cannabis

News

Penny Stocks

Psychedelics

Markets

CLABF

CMPS

ENVB

FLHLF

PHRRF

PSIL

REUN

DHLGY

Minneapolis Mayor Deprioritizes Psychedelics: &#39;We Should Be In The Business Of Helping People&#39;


	Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal prosecution for possession, use, purchase, cultivation and engaging in practices with “entheogenic plants or plant compounds.&#34;


Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa&#39;s Magic Pitch &amp; More

CSE:COOL

GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories Corporation, an arms-length party, in pursuit of a potential transaction involvin

Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds

Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6), (WKN:A3CSSU) announced that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient psilocybin to meet their p

Core One In Talks With Multiple Companies To Supply Psilocybin

Core One Labs Inc

Guidance and investor update
Based on present demand trends and the current fuel price forecast and excluding the impact of special items, the company expects its second-quarter 2024 adjusted earnings per diluted share4 to be between $1.15 and $1.45. The company continues to expect its full-year adjusted earnings per diluted share4 to be between $2.25 and $3.25.

Guidance

American Airlines Q2 Adj. EPS Outlook $1.15 - $1.45 Vs. $1.18 Estimate

American Airlines Reiterates FY24 Adj. EPS Outlook $2.25 - $2.35 Vs. $2.35 Estimate

Visteon is maintaining its full-year 2024&nbsp;guidance&nbsp;and anticipates&nbsp;adjusted EBITDA in the range of&nbsp;$470&nbsp;to&nbsp;$500 million, and adjusted free cash flow in the range of&nbsp;$155&nbsp;to&nbsp;$185 million.

Visteon Maintains Full-Year 2024 Guidance And Anticipates Sales Of $4.0B-$4.2B, Est $4.105B

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) reported quarterly earnings of $1.95 per share which beat the analyst consensus estimate of $1.87 by 4.28 percent. The company reported quarterly sales of $2.094 billion which beat the analyst consensus estimate of $2.035 billion by 2.91 percent. This is a 0.72 percent increase over sales of $2.079 billion the same period last year.

Earnings

Earnings Beats

Dover Q1 2024 Adj EPS $1.95 Beats $1.87 Estimate, Sales $2.094B Beat $2.035B Estimate

Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.24 by 29.17 percent. This is unchanged from the same period last year. The company reported quarterly sales of $101.87 million which beat the analyst consensus estimate of $100.13 million by 1.74 percent. This is a 17.02 percent increase over sales of $87.05 million the same period last year.

Earnings Misses

OPRA

Opera Q1 EPS $0.17 Misses $0.24 Estimate, Sales $101.87M Beat $100.13M Estimate

Baird analyst Luke Junk maintains TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) with a Outperform and lowers the price target from $159 to $158.

Price Target

Analyst Ratings

Baird Maintains Outperform on TE Connectivity, Lowers Price Target to $158

Old Republic Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORI#NYSE">ORI</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.65 by 3.08 percent. This is a 9.84 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $1.849 billion which beat the analyst consensus estimate of $1.844 billion by 0.27 percent. This is a 6.76 percent increase over sales of $1.732 billion the same period last year.

Old Republic Intl Q1 2024 Adj EPS $0.67 Beats $0.65 Estimate, Sales $1.849B Beat $1.844B Estimate

Altria Sees FY24 Adj. EPS $5.05-$5.17 Vs $5.30 Estimate

Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.35 by 8.57 percent. The company reported quarterly sales of $3.470 billion which beat the analyst consensus estimate of $3.407 billion by 1.85 percent. This is a 3.49 percent increase over sales of $3.353 billion the same period last year.

Keurig Dr Pepper Q1 2024 Adj EPS $0.38 Beats $0.35 Estimate, Sales $3.470B Beat $3.407B Estimate

Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) reported quarterly earnings of $0.71 per share which met the analyst consensus estimate. This is a 31.48 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $408.739 million which missed the analyst consensus estimate of $411.332 million by 0.63 percent. This is a 24.14 percent increase over sales of $329.249 million the same period last year.

Tradeweb Markets Q1 2024 Adj EPS $0.71, Inline, Sales $408.739M Miss $411.332M Estimate

Asbury Automotive &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABG#NYSE">ABG</a>) reported quarterly earnings of $7.21 per share which missed the analyst consensus estimate of $7.63 by 5.5 percent.&nbsp;

Asbury Automotive Q1 2024 GAAP EPS $7.21 Misses $7.63 Estimate

American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 780 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $12.570 billion which missed the analyst consensus estimate of $12.602 billion by 0.25 percent. This is a 3.13 percent increase over sales of $12.189 billion the same period last year.

American Airlines Group Q1 2024 Adj EPS $(0.34) Misses $(0.29) Estimate, Sales $12.570B Miss $12.602B Estimate

Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $0.65 by 3.08 percent. The company reported quarterly sales of $1.117 billion which beat the analyst consensus estimate of $1.114 billion by 0.30 percent. This is a 22.21 percent increase over sales of $914.000 million the same period last year.

NDAQ

Nasdaq Q1 2024 Adj EPS $0.63 Misses $0.65 Estimate, Sales $1.117B Beat $1.114B Estimate

Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) reported quarterly earnings of $1.15 per share which met the analyst consensus estimate. The company reported quarterly sales of $5.58 billion which beat the analyst consensus estimate of $4.71 billion by 18.33 percent. This is a 17.07 percent increase over sales of $4.76 billion the same period last year.

Altria Group Q1 2024 GAAP EPS $1.15, Inline, Sales $5.58B Beat $4.71B Estimate

Needham analyst Laura Martin reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Underperform.

Reiteration

Needham Reiterates Underperform on Meta Platforms

Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.99 by 5.05 percent. The company reported quarterly sales of $30.058 billion which beat the analyst consensus estimate of $29.811 billion by 0.83 percent. This is a 1.24 percent increase over sales of $29.691 billion the same period last year.

CMCSA

Comcast Q1 2024 Adj EPS $1.04 Beats $0.99 Estimate, Sales $30.058B Beat $29.811B Estimate

A.O. Smith Reaffirmed FY24 Net Sales Of $3.97B-$4.05B Vs. $4.015B Est.; Adjusted EPS Of $3.90-$4.15 Vs. $4.08 Est.

Garrett Motion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.25 by 12 percent. The company reported quarterly sales of $915.000 million which missed the analyst consensus estimate of $954.500 million by 4.14 percent. This is a 5.67 percent decrease over sales of $970.000 million the same period last year.

Garrett Motion Q1 2024 GAAP EPS $0.28 Beats $0.25 Estimate, Sales $915.000M Miss $954.500M Estimate

Arch Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCH#NYSE">ARCH</a>) reported quarterly earnings of $2.98 per share which missed the analyst consensus estimate of $3.32 by 10.24 percent. The company reported quarterly sales of $680.190 million which beat the analyst consensus estimate of $596.592 million by 14.01 percent. This is a 21.81 percent decrease over sales of $869.931 million the same period last year.

ARCH

Arch Resources Q1 2024 GAAP EPS $2.98 Misses $3.32 Estimate, Sales $680.190M Beat $596.592M Estimate

On Wednesday, April 24, the U.S. stock markets closed mixed&nbsp;as&nbsp;the S&amp;P 500&nbsp;closed&nbsp;higher, influenced by rising Treasury yields following a $70 billion auction and positive tech earnings.&nbsp;
The Dow fell, but the Nasdaq rose, with consumer staples and real estate sectors leading gains.
According to economic data, U.S. mortgage applications dropped 2.7% in the week ending April 19. Meanwhile, orders for durable goods increased by 2.6% in March, and crude oil inventories unexpectedly fell by 6.368 million barrels, defying expectations of a gain.
Seven of the eleven S&amp;P 500 sectors saw advances, with the leading performances in consumer staples, utilities, consumer discretionary, and real estate stocks.
The Dow Jones Industrial Average declined 0.11% to close at 38,460.92. The S&amp;P 500 rose 0.02%, ending the day at 5,071.63, and the Nasdaq Composite climbed 0.10%, finishing the session at 15,712.75.
Asian Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 index closed down 2.16% at 37,628.48. Investors eyed the critical Bank of Japan monetary policy decision on Friday amidst a weakening yen and surging oil prices.</li>
<li>Australia markets closed for ANZAC Day.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.75% at 22,570.35, and the Nifty 500 rose 0.66%, closing at 20,867.90.</li>
<li>China&#8217;s Shanghai Composite gained 0.27% to end the session at 3,052.90, and the Shenzhen CSI 300 rose 0.25%, closing at 3,530.28.</li>
<li>Hong Kong&#8217;s Hang Seng Index gained 0.48%, concluding the day at 17,284.54.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 index was down 0.51%.</li>
<li>Germany&#8217;s DAX declined 0.53%.</li>
<li>France&#8217;s CAC slipped 0.61%.</li>
<li>U.K.&#8217;s FTSE 100 traded higher by 0.64%.</li>
<li>European stocks dipped as traders reacted to mixed earnings from major companies, while the UK&#8217;s FTSE 100 gained, boosted by&nbsp;Anglo American&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38423994/worlds-largest-miner-bhp-bids-to-takeover-anglo-american-as-hunt-for-resources-intensify" rel="noreferrer noopener">surging after a buyout offer from BHP Group</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>).</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.04 % at $82.78/bbl, and Brent was up 0.01% at $88.03 bbl.</li>
<li>Natural Gas declined 0.40% to $1.197.</li>
<li>Gold was trading lower by 0.01% at $2,338.05, Silver gained 0.20% to $27.398, while Copper was up 1.44% at $4.5215.</li>
</ul>
US Futures at 06:00 AM ET&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dow futures were down 0.37%, S&amp;P 500 futures slid 0.53%, and Nasdaq 100 Futures fell 0.82%.
Forex at 06:00 AM ET
The U.S. Dollar Index declined 0.24% to 105.60, USD/JPY was up 0.19% to 155.62, and USD/AUD slipped 0.46% to 1.5319.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Dips; Copper Prices Rise On BHP's Buyout Offer To Anglo American - Global Markets Today While US Slept

Core One Labs signs initial agreement for potential sale of proprietary biosynthetic psilocybin

Press Releases

Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy

Core One in Talks with Multiple Companies to Supply Psilocybin

Biotech

Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method

Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin

Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease

Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass

Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease

Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market